Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oxygen tube aims to make lung scopes safer

NCT ID NCT07389083

Symptom relief Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to give oxygen during a sedated lung scope (bronchoscopy). Normally, patients can have dangerously low oxygen levels because the scope and sedation block the airway. The new method uses a thin, flexible tube placed through the nose to deliver oxygen directly above the voice box. The trial will enroll 50 adults to see if this reduces low-oxygen events compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
wire-reinforced tracheal tube (device)
What this could lead to
If successful, this could offer a safer, more effective way to deliver oxygen during bronchoscopy, reducing the risk of dangerously low oxygen levels.
What could go wrong
This is a small, early-stage feasibility study with only 50 participants. The device may not work as hoped, or could cause discomfort or injury (e.g., nosebleeds).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing fiberoptic bronchoscopy under deep sedation. * Written informed consent obtained from the patient or their legal representative. * Clear understanding of, and voluntary participation in, the study, with informed-consent form signed by the patient or their legal representative. Exclusion Criteria: * Age \< 18 years * BMI \> 30 kg/m² * Previous history of abnormal recovery from anesthesia/surgery * History of recurrent epistaxis, nasal bone fracture, nasal polyps, or sinus surgery * Chronic use of opioid analgesics, benzodiazepine hypnotics, or antidepressant medications * Known allergy to any of the anesthetic agents employed * Anticipated difficult airway * Increased intracranial pressure * Active upper-respiratory-tract infection of the oral, nasal, or pharyngeal regions * Severe cardiac insufficiency (functional capacity \< 4 METs) * Severe renal failure requiring dialysis prior to surgery * Pre-operative oxygen saturation on room air \< 92 % * Any condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypoxia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Deception Hypoxia respiratory tract infectious disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypoxia Pulmonary infection Pulmonary nodule

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.